Literature DB >> 16425357

He Jie Tang in the treatment of chronic hepatitis B patients.

Ze-Xiong Chen1, Shi-Jun Zhang, Shao-Xian Lao, Hong-Tao Hu, Cui-Yi Zhang, Shi-He Guan, Yan-Li Gu.   

Abstract

AIM: To explore the effect of He Jie Tang (decoction for medication) on serum levels of T lymphocyte subsets, NK cell activity and cytokines in chronic hepatitis B patients.
METHODS: Eighty-five patients with chronic hepatitis B were divided randomly into two groups. Fifty patients in group I were treated with He Jie Tang (HJT) and 35 patients in group II were treated with combined medication. The levels of T-lymphocyte subsets (CD(3)(+), CD(4)(+), CD(8)(+)), NK cell activity, cytokines (TNF-alpha, IL-8, sIL-2R) were observed before and after the treatment. Another 20 normal persons served as group 3.
RESULTS: The level of CD(4)(+) cells and NK cell activity were lower, whereas the level of CD(8)(+) cells in patients was higher than that in normal persons (t = 2.685, 3.172, and 2.754 respectively; P<0.01). The levels of TNF-alpha, IL-8, and sIL-2R in chronic hepatitis B patients were higher than those in normal persons (t = 3.526, 3.170, and 2.876 respectively; P<0.01). After 6 months of treatment, ALT, AST, and TB levels in the two groups were obviously decreased (t = 3.421, 3.106, and 2.857 respectively; P<0.01). The level of CD(4)(+) cells and NK cell activity were increased whereas the level of CD(8)(+) cells decreased (t = 2.179, 2.423, and 2.677 respectively; P<0.05) in group I. The levels of TNF-alpha, IL-8, and sIL-2R in group I were decreased significantly after the treatment (t = 2.611, 2.275, and 2.480 respectively; P<0.05) but had no significant difference in group II after the treatment (t = 1.906, 1.833, and 2.029 respectively; P>0.05). The total effective rate had no significant difference between the two groups (c2 = 2.882, P>0.05) but the markedly effective rate was significantly different between the two groups (c2 = 5.340, P<0.05).
CONCLUSION: HJT is effective in treating chronic hepatitis B. HJT seems to exert its effect by improving the cellular immune function and decreasing inflammatory cytokines in chronic hepatitis B patients. The function of HJT in protecting liver function in the process of eliminating virus needs to be further studied.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16425357      PMCID: PMC4355757          DOI: 10.3748/wjg.v11.i42.6638

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  [Effect of hejie decoction on T-cell receptor V beta 7 gene expression in patients of chronic hepatitis B].

Authors:  Shi-jun Zhang; Ze-xiong Chen; Bi-jun Huang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2002-07

2.  Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection.

Authors:  Masahisa Jinushi; Tetsuo Takehara; Tomohide Tatsumi; Tatsuya Kanto; Takuya Miyagi; Takahiro Suzuki; Yoshiyuki Kanazawa; Naoki Hiramatsu; Norio Hayashi
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

3.  Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study.

Authors:  Kenji Ikeda; Masahiro Kobayashi; Satoshi Saitoh; Takashi Someya; Tetsuya Hosaka; Norio Akuta; Yoshiyuki Suzuki; Fumitaka Suzuki; Akihito Tsubota; Yasuji Arase; Hiromitsu Kumada
Journal:  J Gastroenterol Hepatol       Date:  2005-01       Impact factor: 4.029

4.  A pivotal role of IL-12 in Th1-dependent mouse liver injury.

Authors:  Y Tanaka; A Takahashi; K Watanabe; K Takayama; T Yahata; S Habu; T Nishimura
Journal:  Int Immunol       Date:  1996-04       Impact factor: 4.823

5.  Association of serum interleukin-8 levels with the degree of fibrosis in infants with chronic liver disease.

Authors:  Valerio Nobili; Matilde Marcellini; Luigi Giovannelli; Elia Girolami; Flaminia Muratori; Germana Giannone; Rita Devito; Fabrizio De Benedetti
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-11       Impact factor: 2.839

6.  Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers.

Authors:  Maryline Mancini-Bourgine; Hélène Fontaine; Daniel Scott-Algara; Stanislas Pol; Christian Bréchot; Marie-Louise Michel
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

7.  Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.

Authors:  Ingolf Schiefke; Chris Klecker; Melanie Maier; Ute Oesen; Gunnar Etzrodt; Andrea Tannapfel; Uwe G Liebert; Frieder Berr
Journal:  Liver Int       Date:  2004-04       Impact factor: 5.828

8.  Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection.

Authors:  Y Sawayama; J Hayashi; Y Kawakami; N Furusyo; I Ariyama; Y Kishihara; K Ueno; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

9.  Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant.

Authors:  Tatehiro Kagawa; Norihito Watanabe; Hisashi Kanouda; Ichiro Takayama; Tadahiko Shiba; Takashi Kanai; Kazuya Kawazoe; Shinji Takashimizu; Nobue Kumaki; Kazuo Shimamura; Shohei Matsuzaki; Tetsuya Mine
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

10.  HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells.

Authors:  Noriaki Shimada; Kazuhide Yamamoto; Marcelo J Kuroda; Ryo Terada; Tomomi Hakoda; Hiroyuki Shimomura; Hidenori Hata; Eiichi Nakayama; Yasushi Shiratori
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.542

View more
  4 in total

1.  Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.

Authors:  Yu-Ping Wang; Fei Liu; Hong-Wei He; Yan-Xin Han; Zong-Gen Peng; Bao-Wei Li; Xue-Fu You; Dan-Qing Song; Zhuo-Rong Li; Li-Yan Yu; Shan Cen; Bin Hong; Chen-Heng Sun; Li-Xun Zhao; Barry Kreiswirth; David Perlin; Rong-Guang Shao; Jian-Dong Jiang
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies.

Authors:  Don C Rockey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-07       Impact factor: 11.382

3.  Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B.

Authors:  De Zhao Kong; Ning Liang; Guan Lin Yang; Zhe Zhang; Yue Liu; Jing Li; Xuehan Liu; Shibing Liang; Dimitrinka Nikolova; Janus C Jakobsen; Christian Gluud; Jian Ping Liu
Journal:  Cochrane Database Syst Rev       Date:  2019-11-07

4.  Single Oral Dose Toxicity Study of Pinelliae Rhizoma Aqueous Extract in ICR Mice.

Authors:  Young-Kwon Lim; Ji-Ha Park; Bu-Ll Seo; Seong-Soo Roh; Sae-Kwang Ku
Journal:  Toxicol Res       Date:  2009-09-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.